Chemotherapy Sensitizes Colon Cancer Initiating Cells to Vγ9Vδ2 T Cell-Mediated Cytotoxicity

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Todaro, Matilde ^a   Orlando, Valentina ^a   Cicero, Giuseppe ^a   Caccamo, Nadia ^a   Meraviglia, Serena ^a   Stassi, Giorgio ^a   Dieli, Francesco ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; DOXORUBICIN; FAS LIGAND; FLUOROURACIL; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; KLRK1 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CHEMOSENSITIZATION; COLON CANCER; CONTROLLED STUDY; DRUG TARGETING; EX VIVO STUDY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR RECOGNITION; PROTEIN INTERACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADENOCARCINOMA; CELL LINE; COCULTURE; COLONIC NEOPLASMS; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; PATHOLOGY; PRIMARY CELL CULTURE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE; COCULTURE TECHNIQUES; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DOXORUBICIN; FLUOROURACIL; GENE EXPRESSION; HUMANS; NEOPLASTIC STEM CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PRIMARY CELL CULTURE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; T-LYMPHOCYTES, CYTOTOXIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84878804480     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065145     Document Type: Article

References (47)

1. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP, (2008) Cancer stem cells old concepts, new insights. Cell Death Differ 15: 947-958.
2. Koch U, Krause M, Baumann M, (2010) Cancer stem cells at the crossroads of current cancer therapy failures-radiation oncology perspective. Semin Cancer Biol 20: 116-124.
3. Baumann M, Krause M, Hill R, (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8: 545-554.
4. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532.
5. Dean M, Fojo T, Bates S, (2005) Tumour stem cells and drug resistance. Nat. Rev Cancer 5: 275-284.
6. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, et al. (2012) Immunotherapy of cancer in 2012. CA Cancer J Clin 62: 309-335.
7. Hannani D, Ma Y, Yamazaki T, Déchanet-Merville J, Kroemer G, Zitvogel L, (2012) Harnessing γδ T cells in anticancer immunotherapy. Trends Immunol 33: 199-206.
8. Groh V, Porcelli S, Fabbi M, Lanier LL, Picker LJ, et al. (1989) Human lymphocytes bearing T cell receptor γ/δ are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med 169: 1277-1294.
9. Bonneville M, O'Brien RL, Born WK, (2010) γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 10: 467-478.
10. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, et al. (1994) Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science 264: 267-270.
11. Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, et al. (2003) Microbial isoprenoid biosynthesis and human γδ T cell activation. FEBS Lett 544: 4-10.
12. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR, (1995) Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature 375: 155-158.
13. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, et al. (2003) Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197: 163-168.
14. Kistowska M, Rossy E, Sansano S, Gober HJ, Landmann R, et al. (2008) Dysregulation of the host mevalonate pathway during early bacterial infection activates human γδ TCR cells. Eur J Immunol 38: 2200-2220.
15. Sireci G, Espinosa E, Di Sano C, Salerno A, Fournié JJ, et al. (2001) Differential activation of human γδ T cells by nonpeptide phosphoantigens. Eur J Immunol 31: 1628-1634.
16. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, et al. (2007) Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci USA 104: 10022-10027.
17. Vermijlen D, Ellis P, Langford C, Klein A, Engel R, et al. (2007) Distinct cytokine-driven responses of activated blood γδ T cells: insights into unconventional T cell pleiotropy. J Immunol 178: 4304-4314.
18. Wesch D, Glatzel A, Kabelitz D, (2001) Differentiation of resting human peripheral blood γδ T cells toward Th1- or Th2-phenotype. Cell Immunol 212: 110-117.
19. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, et al. (2011) Differentiation, phenotype and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood 118: 129-138.
20. Meraviglia S, Caccamo N, Salerno A, Sireci G, Dieli F, (2010) Partial and ineffective activation of Vγ9Vδ2 T cells by Mycobacterium tuberculosis-infected dendritic cells. J Immunol 185: 1770-1776.
21. Eberl M, Roberts GW, Meuter S, Williams JD, Topley N, et al. (2009) A rapid crosstalk of human γδ T cells and monocytes drives the acute inflammation in bacterial infections. PLoS Pathog 5: e1000308.
22. Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, et al. (2006) CXCR5 identifies a subset of Vγ9Vδ2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. J Immunol 177: 5290-5295.
23. Bansal RR, Mackay CR, Moser B, Eberl M, (2012) IL-21 enhances the potential of human γδ T cells to provide B-cell help. Eur J Immunol 42: 110-119.
24. Caccamo N, Todaro M, La Manna MP, Sireci G, Stassi G, et al. (2012) IL-21 regulates the differentiation of a human γδ T cell subset equipped with B cell helper activity. PLoS One 7: e41940.
25. Mattarollo SR, Kenna T, Nieda M, Nicol AJ, (2007) Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunol Immunother 56: 1285-1297.
26. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, et al. (2011) Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy. J Exp Med 208: 491-503.
27. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, et al. (2009) Efficient killing of human colon cancer stem cells by γδ T lymphocytes. J Immunol 182: 7287-7296.
28. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, et al. (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402.
29. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
30. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, et al. (2005) Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 23: 4110-4116.
31. Linck D, Lentini G, Tiemann M, Fauser AA, Parwaresch R, et al. (2005) Sequential application of chemotherapy and monoclonal CD20 antibody: successful treatment of advanced composite-lymphoma. Leukemia Lymphoma 46: 285-288.
32. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
33. Lake RA, Robinson BW, (2005) Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer 5: 397-405.
34. Mattarollo SR, Kenna T, Nieda M, Nicol AJ, (2006) Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Vα24+ NKT cell-mediated cytotoxicity. Int J Cancer 119: 1630-1637.
35. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, et al. (2005) Vγ9Vδ2 T cell response to colon carcinoma cells. J Immunol 175: 5481-5488.
36. Tong HX, Lu CW, Wang QS, Ma LY, (2011) Combination of IFNγ and chemotherapeutic agents increase TRAIL sensitivity of neuroblastoma cell lines. Eur J Pediatr Surg 21: 304-309.
37. Kang J, Bu J, Hao Y, Chen F, (2005) Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis 8: 274-279.
38. Yoshida S, Narita T, Koshida S, Ohta S, Takeuchi Y, (2003) TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines. Pediatr Res 54: 709-717.
39. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, et al. (2002) Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 99: 491-504.
40. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, et al. (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96: 3900-3906.
41. Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y, (2007) Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci 98: 1969-1976.
42. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S, (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741.
43. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, et al. (1999) Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc Natl Acad Sci USA 96: 6879-6884.
44. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, et al. (2007) Lysis of a broad range of epithelial tumour cells by human γδ T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol 66: 320-328.
45. Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, et al. (2013) Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 21: 638-647.
46. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021.
47. Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, et al. (2010) Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 70: 7500-7513.